The U.S. Food and Drug Administration issued an Emergency Use Authorization (EUA) for the investigational monoclonal antibody therapy, bamlanivimab and etesevimab, administered together, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive COVID-19 test results who are at high risk for progressing to severe COVID-19 and/or hospitalization. Bamlanivimab and etesevimab, administered…
Are you a Member of NAHC?
Become a member or sign in and read full NAHC Report articles at your leisure. Membership is affordable even if you're a small business and it comes with a lot of other benefits.